Pancreatic Cancer Research

ResearcherTeine Keijinkai HospitalNo recent work listed

Hiroaki Ohigashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1681-3044; OpenAlex author ID A5035851945. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 17

  1. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resec… Co-author DOI 10.1097/sla.0000000000005879↗
  2. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.03.015↗
  3. Risk factors for vertebral compression fractures in preoperative chemoradiotherapy with gemcitabine for pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.01.006↗
  4. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical… Co-author DOI 10.1097/sla.0000000000001547↗
  5. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Co-author DOI 10.1016/j.radonc.2015.01.004↗
  6. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on opera… Co-author DOI 10.1016/j.surg.2014.09.022↗
  7. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  8. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy … Co-author DOI 10.1007/s00268-012-1775-x↗
  9. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. First author DOI 10.1097/sla.0b013e31829b3ce4↗
  10. Pancreaticoduodenectomy for invasive pancreatic cancer (with video). First author DOI 10.1007/s00534-011-0467-5↗
  11. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including g… Co-author DOI 10.1007/s00534-012-0514-x↗
  12. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Co-author DOI 10.1097/mpa.0b013e318258055c↗
  13. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based che… First author DOI 10.1097/sla.0b013e31823d813c↗
  14. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage. Co-author DOI 10.1002/gcc.20828↗
  15. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2011.03.001↗
  16. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Co-author DOI 10.1038/onc.2011.59↗
  17. [Neoadjuvant chemoradiation for the pancreatic cancer]. Co-author PMID 21971139↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Osamu Ishikawa · 15 shared papers, 2011–2023 · strength 0.75
  2. Hidenori Takahashi · 14 shared papers, 2011–2023 · strength 0.72
  3. Hirofumi Akita · 5 shared papers, 2011–2023 · strength 0.37
  4. Masato Sakon · 4 shared papers, 2015–2023 · strength 0.35
  5. Masahiko Yano · 7 shared papers, 2011–2017 · strength 0.28
  6. Hidetoshi Eguchi · 4 shared papers, 2011–2023 · strength 0.27
  7. Hiroshi Wada · 1 shared paper, 2023 · strength 0.19
  8. Yasuhiko Tomita · 5 shared papers, 2011–2015 · strength 0.17
  9. Kunihito Gotoh · 5 shared papers, 2011–2015 · strength 0.16
  10. Teruki Teshima · 2 shared papers, 2015–2016 · strength 0.10
  11. Keisuke Otani · 2 shared papers, 2015–2016 · strength 0.10
  12. Koji Konishi · 2 shared papers, 2015–2016 · strength 0.10
  13. Shigeru Marubashi · 3 shared papers, 2011–2015 · strength 0.10
  14. Shigenori Nagata · 2 shared papers, 2012 · strength 0.06
  15. Takashi Hatori · 2 shared papers, 2012–2014 · strength 0.06
  16. Shinichi Egawa · 2 shared papers, 2012–2014 · strength 0.06
  17. Takuji Okusaka · 2 shared papers, 2012–2014 · strength 0.06
  18. Yasuhiro Fujiwara · 1 shared paper, 2017 · strength 0.06
  19. Satoaki Nakamura · 2 shared papers, 2011–2012 · strength 0.05
  20. Yuichiro Doki · 2 shared papers, 2011–2012 · strength 0.05
  21. Takero Hirata · 1 shared paper, 2015 · strength 0.05
  22. Kazuhiko Ogawa · 1 shared paper, 2015 · strength 0.05
  23. Yoshiyuki Fujiwara · 1 shared paper, 2015 · strength 0.04
  24. Hirotada Kittaka · 1 shared paper, 2013 · strength 0.04
  25. Tatsuya Ioka · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.